COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Creatine as a New Therapeutic Strategy in Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00313417
Recruitment Status : Terminated
First Posted : April 12, 2006
Last Update Posted : April 5, 2013
Beersheva Mental Health Center
Information provided by (Responsible Party):
Levine Yossi Prof., Herzog Hospital

Brief Summary:

Creatine as a new therapeutic strategy in depression:

A double-blind, parallel, randomized, add-on clinical trial of creatine versus placebo added to antidepressant treatment of patients with major depressive episode.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Dietary Supplement: Creatine monohydrate Other: Placebo Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Parallel, Randomized, add-on Clinical Trial of Creatine Versus Placebo Added to Antidepressant Treatment of Patients With Major Depressive Episode.
Study Start Date : January 2007
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1 Dietary Supplement: Creatine monohydrate
Up to 10 grams

Placebo Comparator: 2 Other: Placebo
Placebo will be given in the same way and appearance as the active treatment

Primary Outcome Measures :
  1. Hamilton Depression Rating Scale, CGI [ Time Frame: 4 weeks of treatment for each subject ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Age:18-75 -

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00313417

Layout table for location information
Beer Sheva Mental Health Center
Beer Sheva, Israel
Sponsors and Collaborators
Herzog Hospital
Beersheva Mental Health Center
Layout table for investigator information
Principal Investigator: Joseph Levine, Prof. Beer Sheva Mental Health Center Israel.
Principal Investigator: Boris Nemets, Dr. Beer Sheva Mental Health Center Israel.
Layout table for additonal information
Responsible Party: Levine Yossi Prof., HEAD OF PSYCHIATRIC WARD, Herzog Hospital Identifier: NCT00313417    
Other Study ID Numbers: Shapira1CTIL
First Posted: April 12, 2006    Key Record Dates
Last Update Posted: April 5, 2013
Last Verified: April 2013
Keywords provided by Levine Yossi Prof., Herzog Hospital:
major depressive disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms